Table 1.

Patient characteristics

Parameters	Patients with CGM data (N = 39)
Agea (years), mean (range)	14.5 (9, 17)
Female, n (%)	20 (51)
Acceptableb CGM days, n (n/N)c	9474 (242.9)
Days with insulin data, n (n/N)d	6942 (178.0)
Type of smart pen
Basal and bolus	24
Basal only	1
Bolus only	9
Othere	5
Study duration, pen usage (days), mean (range)	343.9 (8, 610)
Time between uploads (days), median (IQR)	78 (63, 113)

CGM continuous glucose monitoring, IQR interquartile range

^aAge at baseline, excluding the age of 1 participant who had an unclear birth date recorded

^bDefined as CGM coverage ≥ 70% over the 24-h period

^cThe median number of CGM days per patient was 246 days (IQR 148, 344)

^dThe median number of days with pen injection and CGM data was 166 days (IQR 46, 288)

^eFive patients were registered with neither bolus nor basal pens specified in the data analyzed; consequently, data from these patients were not incorporated in the analyses of both bolus and basal injections. Of these 5 patients, 3 appeared to have a bolus insulin pen only, but with unspecified insulin type and were, therefore, not included in the bolus analyses. The other 2 patients had both basal and bolus pens in the study period, but did not have any injection data on the CGM days included in the study and were, therefore, also not incorporated in the bolus and basal analyses